Equities

Smith & Nephew PLC

SN.:LSE

Smith & Nephew PLC

Health CareMedical Equipment and Services
  • Price (GBX)992.40
  • Today's Change6.80 / 0.69%
  • Shares traded329.98k
  • 1 Year change-22.38%
  • Beta0.8854
Data delayed at least 20 minutes, as of May 03 2024 10:48 BST.
More ▼

Profile data is unavailable for this security.

About the company

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

  • Revenue in GBP (TTM)4.43bn
  • Net income in GBP209.88m
  • Incorporated1937
  • Employees18.45k
  • Location
    Smith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
  • Phone+44 20 7401 7646Fax+44 20 7930 3353
  • Websitehttps://www.smith-nephew.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SN.:LSE since
announced		Transaction
value
Cartiheal 2009 LtdDeal completed22 Nov 202322 Nov 2023Deal completed-2.90%330.00m
Data delayed at least 20 minutes, as of May 03 2024 10:48 BST.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Medacta Group SA437.01m40.52m1.97bn1.73k1.97bn1.73k
Elekta AB (publ)1.34bn105.16m2.08bn4.58k2.08bn4.58k
Ambu A/S561.94m27.31m3.05bn4.70k3.05bn4.70k
GN Store Nord A/S2.09bn61.51m3.61bn7.05k3.61bn7.05k
Ypsomed Holding AG445.62m63.45m3.92bn2.20k3.92bn2.20k
Getinge AB2.36bn167.62m4.33bn11.86k4.33bn11.86k
SCHOTT Pharma AG & Co KgaA775.07m135.32m4.86bn4.65k4.86bn4.65k
ConvaTec Group PLC1.71bn103.98m5.11bn10.13k5.11bn10.13k
Amplifon SpA1.93bn132.77m6.10bn14.38k6.10bn14.38k
Carl Zeiss Meditec AG1.79bn236.85m7.45bn4.82k7.45bn4.82k
Demant A/S2.58bn292.85m8.25bn21.62k8.25bn21.62k
Smith & Nephew plc4.43bn209.88m8.61bn18.45k8.61bn18.45k
Data as of May 03 2024. Currency figures normalised to Smith & Nephew PLC's reporting currency: UK Pound GBX

Institutional shareholders

28.22%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 31 Dec 202343.82m5.01%
Wellington Management Co. LLPas of 31 Dec 202042.67m4.88%
The Vanguard Group, Inc.as of 02 Apr 202435.10m4.01%
BlackRock Fund Advisorsas of 02 Apr 202421.32m2.44%
Norges Bank Investment Managementas of 02 Apr 202421.26m2.43%
Walter Scott & Partners Ltd.as of 02 Apr 202419.25m2.20%
T. Rowe Price Associates, Inc. (Investment Management)as of 02 Apr 202417.59m2.01%
Rathbones Investment Management Ltd.as of 02 Apr 202416.32m1.87%
Legal & General Investment Management Ltd.as of 02 Apr 202415.48m1.77%
UBS Asset Management (UK) Ltd.as of 02 Apr 202413.97m1.60%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.